← Back to Clinical Trials
Recruiting NCT04616300

NCT04616300 Exercise and Cognitive (Brain) Function in Breast Cancer Patients Getting Chemotherapy After Breast Surgery

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04616300
Status Recruiting
Phase
Sponsor University of Toronto
Condition Breast Cancer
Study Type OBSERVATIONAL
Enrollment 50 participants
Start Date 2019-12-12
Primary Completion 2024-12-31

Eligibility & Interventions

Sex Female only
Min Age 18 Years
Max Age 65 Years
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 50 participants in total. It began in 2019-12-12 with a primary completion date of 2024-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study will primarily identify longitudinal associations between cardiorespiratory fitness (CRF) and cognitive function pre- (baseline) to post-chemotherapy (\~3 months). This will be a prospective study of 50 BCS. We hypothesize that breast cancer patients undergoing chemotherapy who have higher levels of CRF at baseline will have significantly improved measures of attention, executive function, and memory post-chemotherapy. In addition, the exploratory aims will examine the longitudinal associations between physical activity (PA) and cognitive function from pre- to post-chemotherapy and explore the associations between inflammatory and non-inflammatory biomarkers and CRF with cognitive function.

Eligibility Criteria

Inclusion Criteria: * 18-65 years old * histologically-confirmed stage I-III breast cancer, but prior to the initiation of chemotherapy (\<1 cycle of adjuvant therapy or neoadjuvant therapy) * no diagnosed major cognitive disorders and uncontrolled comorbidities. Exclusion Criteria: * received neoadjuvant chemotherapy and scheduled to receive adjuvant chemotherapy * scheduled to receive concurrent radiation therapy with chemotherapy.

Contact & Investigator

Central Contact

Linda Trinh, PhD

✉ linda.trinh@utoronto.ca

📞 (416) 946-3624

Frequently Asked Questions

Who can join the NCT04616300 clinical trial?

This trial is open to female participants only, aged 18 Years or older, up to 65 Years, studying Breast Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04616300 currently recruiting?

Yes, NCT04616300 is actively recruiting participants. Contact the research team at linda.trinh@utoronto.ca for enrollment information.

Where is the NCT04616300 trial being conducted?

This trial is being conducted at Toronto, Canada.

Who is sponsoring the NCT04616300 clinical trial?

NCT04616300 is sponsored by University of Toronto. The trial plans to enroll 50 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology